BioLineRx Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-2.98	-9.22	-60.61	-24.95	-27.05	-30.02
Operating Cash Flow	-13.48	-43.87	-22.61	-26.24	-23.57	-23.21
Capital Expenditures	0.01	-0.05	-0.12	-0.13	-0.1	-
Sale of Property, Plant & Equipment	0.01	-	-	-	-	-
Purchases of Intangible Assets	-0	-0	-0.18	-0.19	-	-
Purchases of Investments	-31.92	-26.35	-47.59	-44	-78	-33.5
Proceeds from Sale of Investments	31.97	55.78	49.33	48.32	39.87	50.17
Investing Cash Flow	2.95	29.37	1.44	4.01	-38.22	16.67
Long-Term Debt Issued	-	19.22	-	9.13	-	-
Long-Term Debt Repaid	-15.33	-14.43	-1.54	-2.83	-3.38	-3.13
Net Long-Term Debt Issued (Repaid)	-15.33	4.79	-1.54	6.29	-3.38	-3.13
Issuance of Common Stock	24.89	16.38	17.04	14.36	61.32	21.22
Net Common Stock Issued (Repurchased)	24.89	16.38	17.04	14.36	61.32	21.22
Other Financing Activities	-0.53	-0.51	-0.45	-0.22	-0.2	-0.22
Financing Cash Flow	12.95	20.66	15.06	20.44	57.75	17.87
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.59	0.02	-0.22	-0.61	0.21	0.21
Net Cash Flow	-1.51	6.16	-6.11	-1.8	-4.05	11.33
Free Cash Flow	-13.48	-43.93	-22.72	-26.37	-23.67	-23.21
FCF Margin	-144.43%	-151.78%	-473.42%	-	-	-
Free Cash Flow Per Share	-	-22.00	-14.15	-20.44	-21.42	-55.07
Levered Free Cash Flow	-16.3	-4.48	-62.27	-18.79	-30.53	-33.15
Unlevered Free Cash Flow	-10.31	-20.46	-49.81	-29.29	-24.87	-22.93

Updated Nov 24, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q